"Axol is a fresh and exciting biotech company founded to fulfil the unmet demand for high quality iPS cell-derived, clinically relevant cells for use in research

Axol specialize in human cell culture. We sell primary cells, iPSC-derived cells and the media and reagents required to successfully culture these cells. We also do iPSC reprogramming and differentiation to various cell types as a service for customers that wish to use their own patient-derived samples.

Axol is headquartered and maintains production on the Chesterford Research Park, a location renowned for inspiring innovation and success, located in Cambridge, UK.

Specialties: iPS cell-derived, clinically relevant cells for use in biomedical research and discovery, Human iPS Cell-Derived Neurons, Custom iPS cell-derived disease relevant human neurons, Primary cells & media, and Custom iPSC-reprogramming and cell differentiation

DISTRIBUTORS
Our trusted partners around the world. All other countries served by Axol directly

ASIA PACIFIC
• China Fujian StemEry
• Indonesia Precision Technologies
• Japan CosmoBio
• Malaysia Precision Technologies
• Singapore Bio-Rev
• South Korea Koma Biotech
• Taiwan Biogenes
• India Biotron
• Israel Danyel Biotech

Axol CEO and Co-founder, Dr Yichen Shi

February 2016: Axol Biosciences hit its overfunding target of £1,000,000 (upped from £700K) on SyndicateRoom.

It takes most biotechnology companies a considerate period of time to achieve revenue and profit stage, yet Axol has already totalled revenues exceeding $1 million from a roster of blue chip clients just two years into the operation.

Current clients include JANSSEN, PFIZER, LILLY and NESTLE, along with HARVARD UNIVERSITY, KINGS COLLEGE LONDON, the UNIVERSITY OF OXFORD and ASTON UNIVERSITY."